Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. FluoGuide A/S
  6. News
  7. Summary
    FLUO   DK0061123312

FLUOGUIDE A/S

(FLUO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

09/14/2021 | 02:01am EDT

FluoGuide A/S announced that FG001 was well tolerated, and light was detected in all patients in the sixth cohort (24 mg), administered in the morning before surgery. The data from the sixth dose (24 mg) showed a continued improvement and clear illumination of the tumors in all three patients. The dose escalation committee has therefore recommended to initiate the seventh dose level (36 mg) in the ongoing clinical phase I/II trial. FluoGuide is conducting a clinical phase I/II trial evaluating safety and efficacy of its lead asset, FG001, in patients with aggressive brain cancer (high grade glioma) undergoing neurosurgery. The Company announced thatFG001 was well tolerated, and an increased illumination of the tumors were detected in all three patients at the sixth dose level (24 mg), administered in the morning before surgery. Based on the strong data, the Company has decided to generate additional safety and dose-selection data by testing 36 mg the morning before surgery, which has been approved by the dose escalation committee. Regarding the illumination, the protocol is designed to continue dose escalation as long as illuminations improve. As this has continuously been observed including with the latest dose of 24 mg, the dose escalation will continue to the next dose level of 36 mg.


© S&P Capital IQ 2021
All news about FLUOGUIDE A/S
10/12FLUOGUIDE A/S : Redeye initiates commissioned research on FluoGuide
AQ
10/12FLUOGUIDE A/S : Redeye Initiates Coverage of Fluoguide
AQ
10/08FLUOGUIDE A/S : FG001 is proven safe in patients undergoing surgery for cancer - a signifi..
AQ
10/08Fluoguide A/S Announces Fg001 Concluds to Be Safe and Well Tolerated by the Dose Escala..
CI
09/14FLUOGUIDE A/S : Receives Positive Response From Sixth Cohort Of Brain Cancer Treatment
MT
09/14FLUOGUIDE A/S : Executive management members and members of the Board of Directors buys sh..
AQ
09/14FLUOGUIDE A/S : proceeds to seventh dose level (36 mg) with FG001 in the ongoing clinical ..
AQ
09/14Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II ..
CI
08/26FLUOGUIDE A/S : announces regulatory approval from Swedish Authorities (MPA and Ethics com..
AQ
08/26FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II C..
CI
More news
Financials
Sales 2020 - - -
Net income 2020 -17,5 M -2,73 M -2,73 M
Net cash 2020 10,4 M 1,63 M 1,63 M
P/E ratio 2020 -49,4x
Yield 2020 -
Capitalization 738 M 115 M 115 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 3
Free-Float 53,1%
Chart FLUOGUIDE A/S
Duration : Period :
FluoGuide A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Morten Albrechtsen Chief Executive Officer
Henrik Kristian Moltke Chief Financial Officer
Arne Ferstad Chairman
Andreas Kjaer Director & Chief Scientific Officer
Dorthe Gronnegaard Mejer Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
FLUOGUIDE A/S0.00%115
THERMO FISHER SCIENTIFIC30.62%240 757
DANAHER CORPORATION39.88%223 934
INTUITIVE SURGICAL, INC.25.24%122 004
SIEMENS HEALTHINEERS AG40.64%77 031
EDWARDS LIFESCIENCES CORPORATION26.87%72 674